← Back to Clinical Trials
Recruiting NCT07678736

NCT07678736 The Muscle Monitor: Early Skeletal Muscle Indicators of Insulin Resistance and Cardiometabolic Risk

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07678736
Status Recruiting
Phase
Sponsor University Ghent
Condition Insulin Resistance
Study Type OBSERVATIONAL
Enrollment 250 participants
Start Date 2025-05-19
Primary Completion 2046-12-31

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 30 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 250 participants in total. It began in 2025-05-19 with a primary completion date of 2046-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Insulin resistance is an early etiological factor in the development of type-2 diabetes (T2D), which constitutes a large societal health burden with an expected additional rise in the years to come. Skeletal muscle is the body's largest lean tissue mass and the major site of glucose disposal in response to insulin stimulation. Prior studies have suggested that a fast skeletal muscle phenotype, including a predominant fast muscle fiber composition, reduced capillary density, low fat oxidation and muscle oxidative capacity may be implicated in insulin resistance and TD2 development. However, key questions pertain in relation to the cause and effect of these relationships as well as the interaction with potential confounders and effect-modifiers including life-style factors (e.g. diet and physical activity levels) and general participant characteristics (e.g. body composition and training status). In the present project, we therefore aim to derive muscle fiber type and extensively map the proteomic signature of the early stages of insulin resistance in a large cross-sectional study using a young and apparently healthy cohort prior to T2D development, including a thorough participant characterization. We will recruit \~250 participants (men and women) in the age of 20-30 years and conduct extensive phenotyping and tissue sampling across one laboratory-based test day and a scan visit, as well as measurements of physical activity level and glucose handling in free-living conditions with wearable sensors. The study has a longitudinal aspect as participants will be re-invited at 5-year intervals for up to 20 years to delineate the trajectory of metabolic health in relation to muscle phenotype measures. The results of the project are expected to lead to significant advancements in our understanding of the importance of muscle phenotype for early-stage insulin resistance and metabolic health trajectories. Such understanding has potentially important clinical implications, as it can open new avenues for targeted interventions and individualized early preventive strategies to counter or delay the progression of insulin resistance and associated metabolic and cardiovascular disorders.

Eligibility Criteria

Inclusion Criteria: * Sex: Males and females * Age: 20-30 years * BMI \<35 * Healthy (no diagnosed chronic disease) Exclusion Criteria: * Chronic disease deemed to affect study outcomes * Disease that increase haemorrhage risk * Daily intake of medication that could confound study outcomes * Regular smokers * Active pregnancy * Immobilization (inactivity due to injury or illness, e.g. cast or brace) for more than a week in the month prior to the study or for more than 4 weeks in the past 6 months prior to the study * Very high structured physical exercise level (\>10 h/week). * Participants not willing to adhere to standardized meal prescriptions included in the study protocols will also be excluded (due to e.g. allergies or specific dietary preferences)

Contact & Investigator

Central Contact

Eline Lievens, Professor

✉ eline.lievens@ugent.be

📞 00320478312585

Frequently Asked Questions

Who can join the NCT07678736 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 30 Years, studying Insulin Resistance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07678736 currently recruiting?

Yes, NCT07678736 is actively recruiting participants. Contact the research team at eline.lievens@ugent.be for enrollment information.

Where is the NCT07678736 trial being conducted?

This trial is being conducted at Ghent, Belgium.

Who is sponsoring the NCT07678736 clinical trial?

NCT07678736 is sponsored by University Ghent. The trial plans to enroll 250 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology